Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Lilly Partners with Ypsomed for AID System; Tidepool Lays Off 40% of Staff

Here is a brief preview of this blast: Two diabetes-related news items have been observed: Lilly and Ypsomed announced a partnership for the commercialization of Ypsomed's AID system and Tidepool announced layoffs accounting for 40% of their staff. Below, FENIX provides highlights and insights for the respective news items, including thoughts on if the Lilly/Ypsomed partnership may be an admission from Lilly that its AID development is behind expectations and how the material experience of Mike Mason may have contributed to this deal getting done.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.